(Q39294069)

10 September 2017

1 reference

title

Polysaccharide conjugate vaccine protein carriers as a "neglected valency" - Potential and limitations (English)

1 reference

10 September 2017

1 reference

Michael Bröker

1

1 reference

10 September 2017

Francesco Berti

series ordinal

2

1 reference

10 September 2017

Joerg Schneider

series ordinal

3

1 reference

10 September 2017

Ivo Vojtek

series ordinal

4

1 reference

10 September 2017

language of work or name

English

0 references

publication date

6 May 2017

1 reference

10 September 2017

1 reference

10 September 2017

volume

35

1 reference

10 September 2017

issue

25

1 reference

10 September 2017

page(s)

3286-3294

1 reference

Potential impact of conjugate pneumococcal vaccines on pediatric pneumococcal diseases

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

7 January 2021

Glycoconjugate vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

CHEMO-IMMUNOLOGICAL STUDIES ON CONJUGATED CARBOHYDRATE-PROTEINS : II. IMMUNOLOGICAL SPECIFICITY OF SYNTHETIC SUGAR-PROTEIN ANTIGENS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Recent mechanistic insights on glycoconjugate vaccines and future perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Novel strategies for development of next-generation glycoconjugate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: a randomized, controlled non-inferiorit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Immunity against Neisseria meningitidis Serogroup C in the Dutch Population before and after Introduction of the Meningococcal C Conjugate Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

MenAfriVac as an Antitetanus Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Biochemical and biological characteristics of cross-reacting material 197 CRM197, a non-toxic mutant of diphtheria toxin: use as a conjugation protein in vaccines and other potential clinical applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Effect of infant immunisation with meningococcus serogroup C-CRM(197) conjugate vaccine on diphtheria immunity and reactogenicity in pre-school aged children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Effect of Tdap when administered before, with or after the 13-valent pneumococcal conjugate vaccine (coadministered with the quadrivalent meningococcal conjugate vaccine) in adults: A randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Booster response to the tetanus and diphtheria toxoid carriers of 11-valent pneumococcal conjugate vaccine in adults and toddlers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Potential protective immunogenicity of tetanus toxoid, diphtheria toxoid and Cross Reacting Material 197 (CRM197) when used as carrier proteins in glycoconjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Carrier priming with CRM 197 or diphtheria toxoid has a different impact on the immunogenicity of the respective glycoconjugates: biophysical and immunochemical interpretation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Protein D of Haemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Developing a nontypeable Haemophilus influenzae (NTHi) vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

PHiD-CV induces anti-Protein D antibodies but does not augment pulmonary clearance of nontypeable Haemophilus influenzae in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and nasopharyngeal carriage in Panamanian children - A randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Effectiveness of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D-Conjugated Vaccine (PHiD-CV) Against Carriage and Acute Otitis Media-A Double-Blind Randomized Clinical Trial in Finland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae among children in São Paulo, Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Reduced middle ear infection with non-typeable Haemophilus influenzae, but not Streptococcus pneumoniae, after transition to 10-valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

General health, otitis media, nasopharyngeal carriage and middle ear microbiology in Northern Territory Aboriginal children vaccinated during consecutive periods of 10-valent or 13-valent pneumococcal conjugate vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Otitis media in children vaccinated during consecutive 7-valent or 10-valent pneumococcal conjugate vaccination schedules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Immunogenicity and safety of an investigational combined haemophilus influenzae type B-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Interactions of conjugate vaccines and co-administered vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Glycoconjugate vaccines and immune interference: A review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

The impact of administration of conjugate vaccines containing cross reacting material on Haemophilus influenzae type b antibody responses in infants: A systematic review and meta-analysis of randomised controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Pertussis vaccination during pregnancy in Belgium: Results of a prospective controlled cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Pertussis vaccination during pregnancy in Belgium: Follow-up of infants until 1 month after the fourth infant pertussis vaccination at 15 months of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Dual-function vaccine for Pseudomonas aeruginosa: characterization of chimeric exotoxin A-pilin protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Safety and Immunogenicity of Escherichia coli 018 O-Specific Polysaccharide (O-PS)-Toxin A and O-PS-Cholera Toxin Conjugate Vaccines in Humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Safety and immunogenicity of Escherichia coli O157 O-specific polysaccharide conjugate vaccine in 2-5-year-old children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Safety And Immunogenicity Of A Polyvalent Escherichia Coli Vaccine In Human Volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Synthesis and characterization of a polyvalent Escherichia coli O-polysaccharide-toxin A conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Persistent Efficacy of Vi Conjugate Vaccine against Typhoid Fever in Young Children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: A single blind, partially randomized Phase I study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Extraintestinal Pathogenic Escherichia coli, a Common Human Pathogen: Challenges for Vaccine Development and Progress in the Field

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Efficacy of a conjugate vaccine containing polymannuronic acid and flagellin against experimental Pseudomonas aeruginosa lung infection in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Clostridium difficile recombinant toxin A repeating units as a carrier protein for conjugate vaccines: studies of pneumococcal type 14, Escherichia coli K1, and Shigella flexneri type 2a polysaccharides in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Recombinant Clostridium difficile toxin fragments as carrier protein for PSII surface polysaccharide preserve their neutralizing activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Tyrosine-directed conjugation of large glycans to proteins via copper-free click chemistry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Anti-Group B Streptococcus Glycan-Conjugate Vaccines Using Pilus Protein GBS80 As Carrier and Antigen: Comparing Lysine and Tyrosine-directed Conjugation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Identification of a universal Group B streptococcus vaccine by multiple genome screen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Exploring the Effect of Conjugation Site and Chemistry on the Immunogenicity of an anti-Group B Streptococcus Glycoconjugate Vaccine Based on GBS67 Pilus Protein and Type V Polysaccharide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Rationale and prospects for novel pneumococcal vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Conjugation of polysaccharide 6B from Streptococcus pneumoniae with pneumococcal surface protein A: PspA conformation and its effect on the immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Humoral immune response of a pneumococcal conjugate vaccine: Capsular polysaccharide serotype 14—Lysine modified PspA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Randomized controlled study of the safety and immunogenicity of pneumococcal vaccine formulations containing PhtD and detoxified pneumolysin with alum or adjuvant system AS02V in elderly adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Preclinical studies on new proteins as carrier for glycoconjugate vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

A Poly-N-acetylglucosamine-Shiga toxin broad-spectrum conjugate vaccine for Shiga toxin-producing Escherichia coli.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

Serum antibody responses of juvenile and infant rhesus monkeys injected with Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-protein conjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

7 January 2021

Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

7 January 2021

Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

7 January 2021

Protection against experimental Pseudomonas aeruginosa infection in mice by active immunization with exotoxin A toxoids.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

7 January 2021

Syntheses and immunologic properties of Escherichia coli O157 O-specific polysaccharide and Shiga toxin 1 B subunit conjugates in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.078

7 January 2021

10.1016/J.VACCINE.2017.04.078

Identifiers

DOI

1 reference

10 September 2017

1 reference